GSK announces appointment of Philippe Fauchet as President of GSK Japan

GSK today announces the appointment of Philippe Fauchet as President of GSK Japan. Philippe will report to Marc Dunoyer, who takes the new role as Chairman of GSK Japan. Marc will continue to take overall leadership responsibility for GSK’s Pharmaceuticals business across the Asia Pacific/ Japan Region.

Issued: Thursday 4 February 2010, London UK

GSK today announces the appointment of Philippe Fauchet as President of GSK Japan. Philippe will report to Marc Dunoyer, who takes the new role as Chairman of GSK Japan. Marc will continue to take overall leadership responsibility for GSK’s Pharmaceuticals business across the Asia Pacific/ Japan Region.

Philippe joins GSK from Sanofi Aventis where he was Senior Vice President, Business Development. He joined Sanofi in 1996, and headed up the Eastern Europe region from 1997, before becoming Vice President, Eastern Europe for Sanofi-Synthélabo in 1999. Philippe Fauchet took over as head of Sanofi-Synthélabo’s Japanese operations in June 2001 and was appointed as Senior Vice President Pharmaceuticals Operations, Japan in May 2005.

Philippe is a graduate of HEC (Ecole des Hautes Etudes Commerciales), and also holds a law degree. He joined Roussel Uclaf in 1984, and held a number of posts in France, Japan and Korea, before becoming Vice President of the Asia-Pacific region for Hoechst Marion Roussel in 1995.

Marc Dunoyer, GSK’s President of Asia Pacific and Chairman of Japan, said: “The depth of knowledge and experience Philippe gained through previous roles in Japan, his general business and commercial acumen and his proven leadership skills make him ideally suited to drive the growth of this key business. Over the next five years we have the potential to launch between 30 and 40 products in Japan and I look forward to working with Philippe to maximise this opportunity.”

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

GlaxoSmithKline Enquiries:

UK Media enquiries:

Philip Thomson

(020) 8047 5502

 

Claire Brough

(020) 8047 5502

 

Stephen Rea

(020) 8047 5502

 

Alexandra Harrison

(020) 8047 5502

 

Jo Revill

(020) 8047 5502

 

 

 

US Media enquiries:

Nancy Pekarek

(919) 483 2839

 

Mary Anne Rhyne

(919) 483 2839

 

Kevin Colgan

(919) 483 2839

 

Sarah Alspach

(919) 483 2839

 

European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564

Sally Ferguson

(020) 8047 5543

Gary Davies

(020) 8047 5503

US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419

Jen Hill Baxter

(215) 751 7002